BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Kolon claims its arthritis gene therapy medicine is effective for 36 months

Park Sae-jin Reporter(swatchsjp@ajunews.com) | Posted : July 31, 2018, 17:08 | Updated : July 31, 2018, 17:08
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Kolon Life Science]


SEOUL -- Based on the long-term tracking result of phase 3 clinical tests at home, Kolon Life Science, the biosimilar arm of South Korea's Kolon Group, said Invossa, the world's first cell-mediated gene therapy for degenerative arthritis, proved to be effective in improving joint functions for up to 36 months.

Kolon Life claimed that a single injection of Invossa could grant more than two years of pain-free movement in the knee without the immediate need for surgery when it received marketing approval from the Korea Ministry of Food and Drug Safety last year.

At the annual meeting of Japan Society of Gene and Cell Therapy (JSGCT) in Tokyo last week, Kolon Life reported that the administration of Invossa can delay a patient's need for a knee surgery.

Clinical data showed that six out of 81 patients injected with a placebo drug received a knee surgery while only one out of 78 patients injected with Invossa needed a knee operation, Kolon Life's managing director Yoo Soo-hyun said. "The possibility that the injection of Invosa could delay the operation of artificial joints was confirmed."

Kolon TissueGene, the U.S subsidiary of Kolon Life Science, has been allowed to conduct phase 3 clinical trials involving some 1,020 patients diagnosed with knee osteoarthritis at 60 American hospitals.

Clinical trials at American hospitals would involve patients with light orthopedic symptoms in the knee. Kolon described Invossa as a game changer in the global degenerative joint disease market and vowed to seek approval from the U.S. Food and Drug Administration in 2021.




  • Park Sae-jin Reporter
  • email : swatchsjp@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .U.S. company Mundipharma wins contract to launch Kolons Invossa in Japan.
    U.S. company Mundipharma wins contract to launch Kolon's Inv…
  • .Kolon wins contract to sell arthritis gene therapy in Chinas Hainan.
    Kolon wins contract to sell arthritis gene therapy in China'…
  • .TissueGenes osteoarthritis therapy allowed to conduct U.S. clinical trials.
    TissueGene's osteoarthritis therapy allowed to conduct U.S. …
  • .Kolon exports worlds first arthritis gene therapy tech for $438 mil.
    Kolon exports world's first arthritis gene therapy tech for …

Real Time Photo News

  • .BTS wants fan club to collaborate in creating web memory archive.

    BTS wants fan club to collaborate in creating web memory archive

  • .Debut album of BTS brother band receives more than 100,000 pre-orders.

    Debut album of BTS brother band receives more than 100,000 pre-orders

  • .SM Entertainment agrees to set up joint venture with Indonesian media company.

    SM Entertainment agrees to set up joint venture with Indonesian media company

  • .Girl band AOAs Seolhyun stars in cable TVs historical period drama .

    Girl band AOA's Seolhyun stars in cable TV's historical period drama

  • .BTS becomes first K-pop band to go on global stadium tour.

    BTS becomes first K-pop band to go on global stadium tour

Latest News

more+

  • BTS wants fan club to collaborate in creating web memory archive
  • [FOCUS] Netmarble and others participate in preliminary bidding for Nexon
  • Debut album of BTS brother band receives more than 100,000 pre-orders
  • S. Korea and India agree to step up cooperation in military and space sectors
  • Samsung develops next-gen chipset for 5G base stations
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view